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Materials and Methods 
 Unless otherwise noted, all chemicals and reagents for chemical reactions were obtained from 
commercial suppliers (Sigma, Aldrich, Fluka, Wako Chemicals, Toronto Research, Carbosynth, Fischer 
Scientific, MP Biomedicals, TCI America) and used without purification.  Solvents used in the synthesis 
of substrates were obtained from a Seca Solvent System by GlassContour (solvent dried over alumina 
under a N2 atmosphere).  Chemical reactions were prepared in flame or oven-dried glassware under an 
inert N2 atmosphere using either syringe or cannula techniques.  Bioconversions were conducted open to 
the atmosphere in large crystallization dishes with stirring provided by a magnetic stir bar/plate. Silica gel 
chromatography purifications were carried out using AMD Silica Gel 60, 230-400 mesh.  1H, 13C, and 19F 
NMR spectra were recorded on either a Varian Mercury 300 spectrometer (300 MHz, 75 MHz, and 282 
MHz, respectively), a Bruker DRX-600 spectrometer equipped with a CryoProbe (600 MHz and 
150 MHz for 1H and 13C),  or a Varian Inova 600 spectrometer (600 MHz and 150 MHz for 1H and 13C), 
and are internally referenced to residual solvent peak.  Data for 1H NMR are reported in the conventional 
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form: chemical shift (δ ppm), multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, 
br=broad), coupling constant (Hz), integration.  Data for 13C and 19F NMR are reported in the terms of 
chemical shift (δ ppm) and multiplicity. High-resolution mass spectra were obtained with a JEOL JMS-
600H High Resolution Mass Spectrometer at the California Institute of Technology Mass Spectral 
Facility or an Agilent 6210 Time of Flight Mass Spectrometer at The Scripps Research Insititue Center 
for Mass Spectrometry.  Reactions were monitored using thin layer chromatography  (Merck 60 silica gel 
plates) using a 5% aqueous H2SO4 solution and heat as visualizing agent.   
 Gas chromatography (GC) analyses were carried out using a Shimadzu GC-17A gas chromatograph, 
a FID detector, and an Agilent HP5 column (30 m x 0.32 mm x 0.1 µm film).  GC-MS analyses were 
carried out on a Hewlett-Packard 5970B MSD with 5890 GC and a DB-5 capillary column.  For 
permethylated monosaccharides: Start at 35 °C and hold for 10 min, then ramp at 5 °C/min to 150 °C and 
hold for 5 min, then ramp at 30 °C/min to 300 °C and hold for 5 min.  For other compounds: start at 100 
°C, hold for 2.5 min, then ramp at 10 °C/min to 168 °C, hold 2 min, then ramp at 0.1 °C/min to 171 °C, 
hold for 1 min, then 25 °C. min to 300 °C. 
 Complete analytical data and synthesis procedures have been reported in the literature for:  1,2,3,4,6-
pentamethyl-α-glucopyranoside (1),1 1,2,3,4,6-pentamethyl-α-galactopyranoside (2),2 1,2,3,4,6-
pentamethyl-α-mannopyranoside (3),3 1-benzyl-2,3,4,6-tetramethyl-β-glucopyranoside (4),4 1,2,3,4,6-
pentamethyl-β-galactopyranoside (5),5 1-acetyl-2,3,4,6-tetramethyl-β-galactopyranoside (8).6   
Plasmid pCWori[BM3] was used as cloning vector.  Oligonucleotides were purchased from 
Integrated DNA Technologies (IDT, San Diego, CA), and the sequences of the primers used in this study 
are reported below.  Electro-competent Escherichia coli cells were prepared following the protocol of 
Sambrook et al.7  Restriction enzymes BamHI and SacI, Phusion polymerase, and T4 ligase were 
purchased from New England Biolabs (NEB, Ipswich, MA).  Alkaline phosphatase was obtained from 
Roche (Nutley, NJ).  AmpliTaq was purchased from Applied Biosystems (Foster City, CA).  The 
modified trace metal mix used in expression cultures was reported by Studier.8 
General Procedures 
Enzyme Library Screening.  Libraries maintained in our laboratory, including the compilation 
library and the active site library, are stored at -78 °C as glycerol stocks (Luria-Bertani medium (LBamp)), 
150 µL, 20% v/v LB/glycerol with 0.1 mg/mL ampicillin) in 96-well plates.  These stocks were used to 
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inoculate 96-well deep-well plates containing 300 µL LBamp medium using a 96-pin stamp.  Single 
colonies from error prone PCR or recombination libraries were picked by a Qpix robot (Genetix, 
Beaverton, OR) and used to inoculate 300 µl of LBamp.  The cells were incubated at 37 °C, 225 rpm, and 
80% relative humidity over night.  After 16 h, 50 µL aliquots of these over night cultures were transferred 
into 2 mL, deep-well plates containing terrific broth (TBamp) (800 µL containing 0.1 mg/mL ampicillin 
and 1 µL/mL trace metal mix) using a Multimek 96-channel pipetting robot (Beckman Coulter, Fullerton, 
CA).  The cultures were incubated at 37 °C for 4 h, and 30 min after reducing the incubation temperature 
to 25°C (225 rpm and 80% relative humidity), 50 µL isopropyl β-D-1-thiogalactopyranoside (IPTG, 4.5 
mM in TBamp) was added, and the cultures were allowed to continue for another 24 h at 25 °C (225 rpm 
and 80% relative humidity).  Cells were then pelleted (3,000xg, 15 min, 4 °C) and stored at -20 °C until 
further use but at least for 2 h. For cell lysis, plates were allowed to thaw for 30 min at room temperature 
and then cell pellets were resuspended in 300 µL phosphate buffer (0.1 M, pH = 8, 0.75 mg/mL lysozyme 
and 40 U/mL DNase I).  The lysing cells were incubated at 37 °C for 1 h, and then the cell debris was 
separated by centrifugation at 5,000xg and 4 °C for 15 min.  The resulting crude lysates were then 
transferred to 96-well microtiter plates for assay. 
High Throughput Colorimetric Assay.  BM3 variants in cell lysate (40 µL) were diluted with 
phosphate buffer (200 µL final reaction volume, 0.1 M, pH = 8).  The appropriate substrate (1 mM final 
substrate concentration) in either phosphate buffer (0.1 M, pH = 8) or DMSO (final concentration no 
greater than 2.5% v/v) was added, and the reactions were initiated by addition of a solution of NADPH in 
phosphate buffer (0.5 mM final NADPH concentration, 0.1 M phosphate buffer, pH = 8).  After 2 h, the 
reactions were quenched by addition of 50 µL Purpald solution (0.16 M in 2M NaOH), and the 
absorbance of the mixtures at 550 nm was measured after 30-45 min using a plate reader.9 
CO Binding Assay.  BM3 variants in cell lysate (40 µL) were diluted with 60 µL phosphate buffer 
(0.1 M, pH = 8).  To this solution was added 100 µL sodium dithionite (0.3 M in phosphate buffer, 1 M, 
pH = 8).  The absorbance at 450 and 490 nm was recorded using a plate reader, and the microtiter plates 
were placed in a vacuum chamber.  The chamber was sealed, evacuated to approximately -15 in Hg, 
purged with CO gas, and incubated for 20 min.  The plates were then removed and the aborbance at 450 
and 490 nm was again recorded using a plate reader.  The difference spectra could then be used to 
determine the P450 concentration in each well as previously reported.10 
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Site-Directed Mutagenesis.  Base pair mutations were introduced into the genes coding for variants 
9-10A F87I, 2C6, E12, and B1 by site directed overlap extension (SOE) PCR.  For each mutation, two 
separate PCRs were performed, each using a perfectly complementary flanking primer at the 5’ and 3’ 
end of the sequence and a mutagenic primer.  The PCR conditions were as follows:  Phusion HF buffer 
1x, 0.2 mM dNTPs each, 0.5 µM forward primer, 0.5 µM reverse primer, and 0.02 U/µl Phusion 
polymerase. The resulting two overlapping fragments that contained the base pair substitution were then 
assembled in a second PCR using the flanking primers resulting in the full length mutated gene.  For:  
F87Idr, 2C6dr, E12r12, B1SYN:  
# Primer Name Sequence 
1 dr_C47R_for 5' - CGA GGC GCC TGG TCG TGT AAC GCG CTA C - 3' 
2 dr_C47R_rev 5' - GTA GCG CGT TAC ACG ACC AGG CGC CTC G - 3' 
3 dr_I94K_for 5' - GCT GGA CGC ATG AAA AAA ATT GGA AAA AAG CG - 3' 
4 dr_I94K_rev 5' - CGC TTT TTT CCA ATT TTT TTC ATG CGT CCA GC - 3' 
5 E12r12_V111A_fwd 5' - TAG TCA GCA GGC AAT GAA AGG CTA TCA - 3' 
6 E12r12_I141V_fwd 5' - TGA TAG CCT TTC ATT GCC TGC TGA CTA - 3' 
7 E12r12_V111A_rev 5' - GAG CAT ATT GAA GTA TCG GAA GAC ATG - 3' 
8 E12r12_I141V_rev 5' - CAT GTC TTC CGA TAC TTC AAT ATG CTC - 3' 
9 B1SYN_R47S_fwd 5' - AGG CGC CTG GTA GTG TAA CGC GCT ACT - 3' 
10 B1SYN_N70Y_fwd 5' - CAC GCT TTG ATA AAT ACT TAA GTC AAG CCT TG - 3' 
11 B1SYN_I174N_fwd 5' - CAG CCT CAT CCA TTT AAT ATA AGT ATG GTC - 3' 
12 B1SYN_R47S_rev 5' - AGT AGC GCG TTA CAC TAC CAG GCG CCT - 3' 
13 B1SYN_N70Y_rev 5' - CAA GGC TTG ACT TAA GTA TTT ATC AAA GCG TG - 3' 
14 B1SYN_I174N_rev 5' - GAC CAT ACT TAT ATT AAA TGG ATG AGG CTG - 3' 
15 Heme Fwd1 5' - CAG GAA ACA GGA TCA GCT TAC TCC CC - 3' 
16 Heme Rev1 5' - CGC GCC GTT CCT TCA GCT GTT CCC - 3' 
 
Radom Mutagenesis.  A library of 2C6dr mutants was created by error prone PCR using the 
GeneMorph II Random Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer’s 
protocol, using 75 ng template DNA (2C6dr) to generate approximately 2.5 nucleotide (nt) 
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mutations/gene and flanking primers HF1 and HR2.  After transforming electro-competent E. coli 
DH5α cells with the desalted ligation mixture, cells were allowed to recover in SOC medium (37 °C, 
45 min), plated then onto LBamp agar plates (6.25 g LB powder mix, 4 g agar, 250 mL DDI water, 0.1 
mg/mL ampicillin), and incubated at 37 °C for 16 h.  Approximately 3,000 clones from this library were 
picked as previously described.   
Variants B1, D3, A8, A11, and E12 were obtained from this library.  Site directed mutagenesis using 
SOE PCR was then carried out as described above in order to introduce N70Y, I174N, and R47S into the 
gene encoding B1 to create variant B1SYN.  Similarly, A111V and V141I were reverted in E12 in order 
to create E12R12, and F87V was introduced in order to create E12r12 F87V. 
# Variant Mutation 
1 B1 I263M 
2 D3 N70Y 
3 A8 I174N 
4 A11 R47S, W96R 
5 E12 A111V, V141I, A180V 
A library of E12r12 F87V mutants was created by error prone PCR using AmpliTaq DNA 
polymerase (Applied Biosystems, Foster City, CA) and varying amounts of MnCl2 to introduce the 
desired error rate.  The following PCR conditions gave the best fraction folded while introducing 2.5 nt 
exchanges per gene:  1x reaction buffer, 0.4 mM of each dNTP, 4 U AmpliTaq, 7 mM MgCl2, 0.15 mM 
MnCl2, 0.2 mM of each primer HF1 and HR2.  The transformed cells were plated on LBamp agar plates as 
decribed above, and approximately 3,600 variants were picked.  Variants 3E11, 7F3, 9C7, 32E11, and 
33A8 were obtained from this library.   
# Variant Mutation 
1 3E11 F158L 
2 7F3 V87A, K210M, H266Q 
3 9C7 V87G, Y345C 
4 32E11 V87A, K241R, N283Y 
5 33A8 N70Y, M112T 
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Recombination of Active Variants.  Mutations F158L, K210M, H266Q, Y345C, K241R, N283Y, 
N70Y, and M112T were recombined with 9C7 as template. The recombination library was constructed 
using SOE PCR introducing the eight mutations found in the five variants while allowing for the 9C7 
sequence as well.  Nine fragments were generated using either a combination of a flanking primer and a 
mutagenic primer or two mutagenic primers.  Fragments 1-3, 4-6, and 7-9 were assembled in three 
separate reactions, and the resulting fragments 1’, 2’, and 3’ were assembled in a final PCR step.    
After transforming electro-competent E. coli DH5α cells with the desalted ligation mixture, cells 
were allowed to recover in SOC medium (37 °C, 45 min), plated then onto LBamp agar plates (6.25 g LB 
powder mix, 4 g agar, 250 mL DDI water, 0.1 mg/mL ampicillin), and were incubated at 37 °C for 16 h. 
Approximately 1,000 clones from this library were picked as previously described from which variant 
5E5 was obtained. 
# Primer Name Sequence 
1 N70recfwd CAC GCT TTG ATA AAW ACT TAA GTC AAG CCT T 
2 
N70recrev AAG GCT TGA CTT AAG TWT TTA TCA AAG CGT G 
3 
M112recfwd TAG TCA GCA GGC AAY GAA AGG CTA TCA T 
4 
M112recrev ATG ATA GCC TTT CRT TGC CTG CTG ACT A 
5 
F158recfwd GGT CTT TGC GGC TTT KAC TAT CGC TTT AAC 
6 
F158recrev GTT AAA GCG ATA GTM AAA GCC GCA AAG ACC 
7 
K210recfwd GTC AAG AAG ATA TCA WGG TGA TGA ACG ACC TA 
8 
K210recrev TAG GTC GTT CAT CAC CWT GAT ATC TTC TTG AC 
9 
K241recfwd GAT GCT AAA CGG AAR AGA TCC AGA AAC G 
10 
K241recrev CGT TTC TGG ATC TYT TCC GTT TAG CAT C 
11 
H266recfwd TTA ATT GCG GGA CAK GAA ACA ACA AGT 
12 
H266recrev ACT TGT TGT TTC MTG TCC CGC AAT TAA 
13 
N283recfwd TAT TTC TTA GTG AAA WAT CCA CAT GTA TTA CAA 
14 
N283recrev TTG TAA TAC ATG TGG ATW TTT CAC TAA GAA ATA 
15 
Y345recfwd GCT TGG AGG AGA ATR CCC TTT AGA AAA AG 
16 
Y345recrev CTT TTT CTA AAG GGY ATT CTC CTC CAA GC 
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Summary of enzymes utilized for synthesis of monosaccharide derivatives. 
 
Enzyme Amino acid mutations compared to wildtype P450BM3 
9-10A11 R47C, V78A, K94I, P142S,T175I, A184V, F205C, S226R, H236Q, E252G, R255S, 
A290V, L353V 
2C6 9-10A A78L F87A V184T G315S A330V 
2C6dr 9-10A C47R A78L F87A I94K V184T G315S A330V 
E12 2C6dr A111V V141I A180V 
E12r12 2C6dr A180V 
B1 2C6dr I263M 
B1SYN B1 R47S N70Y I174N 
9-10A F87Idr 9-10A R47S F87I I174N 
9-10A F87Vdr 9-10A R47S F87V I174N 
9C7 E12r12 A87G Y345C 
5E5 9C7 N70Y N159D K241R H266Q C345Y 
 
 
P450 Expression and Purification.  For the chemo-enzymatic transformations, P450BM3 enzyme 
variants were used in purified form.  Enzyme batches were prepared as follows.  Two liters TBamp were 
inoculated with an overnight culture (100 mL, LBamp) of recombinant E. coli DH5α cells harboring a 
pCWori plasmid encoding for the P450 variant under the control of Plac promoter.  At an OD600 of 1.8 
(ca. 3-4 h), the incubation temperature was reduced to 25˚C (30 min), and the cultures were induced by 
adding IPTG to a final concentration of 0.1 mM.  The cultures were allowed to continue for another 24 
 8 
hours at this temperature.  After harvesting the cells by centrifugation (4 °C, 15 min, 3000xg), the cell 
pellet was resuspended in 25 mM TRIS-HCl buffer (pH 8.0) and cells were disrupted by sonication 
(4x1min, 50% duty cycle).  Cell debris was removed by centrifugation for 20 min at 4 °C and 20000xg 
and the resulting cell lysate was loaded onto a Q resin and the column was washed with three column 
volumes (cv) of 25 mM TRIS-HCl (pH 8.0), 150 mM NaCl.  Bound protein was eluted with 25 mM 
TRIS-HCl (pH 8.0), 340 mM NaCl and concentrated using Millipore Centricon tubes.  After buffer 
exchange with 100 mM KPi (pH 8.0), protein samples were frozen and stored at -80 °C.  Protein 
concentration was determined in duplicate from CO-difference spectra as previously described.  Yields 
typically ranged between 100 and 500 mg protein per liter depending on the variant.  
Typical Procedure for Medium-Scale Bioconversions.  To a well of a 24-well plate was added 
potassium phosphate buffer (100 mM, pH 8, 0.5-1 mL final reaction volume) and a solution of the desired 
substrate in phosphate buffer or DMSO (1 equiv, 1 mM final concentration).  A solution of NADP+ (0.5 
equiv, 0.5 mM final concentration), glucose-6-phosphate (40 equiv, 40 mM final concentration), glucose-
6-phosphate dehydrogenase (2 units/mL final reaction volume), and superoxide dismutase (100 units/mL 
final reaction volume) was added.  A solution of the appropriate BM3 variant (1 µM final concentration) 
was added, the plate was loosely fitted with its lid, and the plate was shaken at 35 rpm.  Following the 
desired reaction time, a 0.4 mL aliquot was removed and combined with 0.2 mL CHCl3 containing 
approximately 1 mM tetradecane.  The mixture was thoroughly vortexed and the resulting suspension was 
centrifuged at 10,000 rpm for 1 min.  The organic phase was transfered to a GC vial and analyzed by GC.   
Typical Procedure for Preparative-Scale Bioconversions.  To a 100 x 50 mm  crystallizing dish 
(ie. ChemGlass #CG-8276-100) was added potassium phosphate buffer (100 mM, pH 8) and a solution of 
the desired substrate in phosphate buffer or DMSO (1 equiv, 5 mM final concentration).  A solution of 
NADP+ (0.1 equiv, 0.5 mM final concentration), glucose-6-phosphate (10 equiv, 50 mM final 
concentration), and glucose-6-phosphate dehydrogenase (2 units/mL final reaction volume) was added.  A 
solution of the appropriate BM3 variant (0.001 equiv, 5 µM final concentration) was added, the dish was 
loosely covered with aluminum foil, and stirred using a magnetic stir bar.  The moderate stir rate was 
utilized to allow efficient O2 transfer to the reaction mixture while avoiding foaming.  The reaction 
progress could be monitored by analyzing aliquots of the reaction mixture as described for the medium 
scale bioconversions.  After 12 h, the reaction mixture was transferred to a separatory funnel.  The 
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mixture was extracted with 4 x 75 mL CH2Cl2.  Emulsions formed following agitation of the separatory 
funnel and complete phase separation was not typically observed.  The mixture was allowed to sit 
approximately 5-10 min after each agitation in order to obtain a distinct boundary between the aqueous 
phase and the emulsion.  The combined emulsion layers were then filtered through Celite to break the 
emulsion and the Celite pad was rinsed with 3x20 mL CH2Cl2.  The resulting biphasic mixture was 
transfered to a separatory funnel and the organic phase was removed.  The remaining aqueous phase was 
re-extracted with 3x10 mL CH2Cl2.  The combined organic extracts were dried with sodium sulfate, 
filtered, and concentrated.  The resulting residue was purified by SiO2 chromatography eluting with 
ethylacetate/hexanes. 
We have subsequently found that the workup procedure can be greatly simplified by adjusting the pH 
of the reaction mixture to <4 and saturating the solution with brine.  This has the effect of precipitating 
most of the protein from solution and improving the efficiency for the extraction of the hydrophilic 
monosaccharide product from the mixture.  The resulting suspension is then filtered through Celite, which 
is rinsed with methylene chloride in order to provide a biphasic mixture.  The organic phase can then be 
cleanly separated, and the aqueous phase can be extracted without any complication from emulsions. 
Colorimetric analysis of formaldehyde produced from various galactose substrates 
A 
O
MeO
MeO
OMe OR1
OMe P450, 0.5 mM NADPH
0-5% DMSO/ KPi 
(100 mM, pH8)
              -CH2O
O
R2O
R2O
OR2 OR1
OR2 R1 = αMe (2), βMe (5),
         βBn (6), βBz (7),
         and βAc (8)
R2 = H, Me
1 mM  
B 
 
(A) Reaction conditions used for colorimetric analysis.  (B) [CH2O] determined by colorimetric analysis 
of CH2O-purpald adduct at 550 nm relative known concentrations of this species within the linear range 
of the assay.  1 µM (0.1 mol%) BM3 variant used. 
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Synthesis of Substrates and Standards for Initial Screens 
 
O
OMeHO
O
OPh
HO
1-E
O
OMeBnO
O
OPh
HO
O
OMeHO
O
OPh
BnO
1-F
1-G
2:1, 1-F:1-G
i. Bu2SnO, 
   MeOH, 
   reflux
ii. BnBr, DMF,
   100 °C
        52%
+
O
OMeBnO
MeO
MeO
MeO
O
OMeMeO
MeO
MeO
BnO
1-H
1-I
i. 70% HOAc, 
   70 °C
ii. MeI, DMSO
    50% NaOH 
         44%
O
OMeHO
MeO
MeO
MeO
O
OMeMeO
MeO
MeO
HO
1-A
1-B
20% Pd(OH)2,
H2, 2:1 DMF
EtOAc
         95%
i. 70% HOAc, 
   70 °C
ii. MeI, DMSO
    50% NaOH 
         44%
20% Pd(OH)2,
H2, 2:1 DMF
EtOAc
         95%
 
α-methyl-3,4,6-triemthylglucopyranoside (1-A).  1-Methyl-4,6-O-(phenylmethylene)-α-D-
glucopyranoside, 1-E, (200 mg, 0.7 mmol) and Bu2SnO (192 mg, 760 mmol) were suspended in 6 ml 
MeOH and heated to reflux.  After 1.5 h, the solution was cooled to room temperature and concentrated.  
The resulting oil was pumped on under high vacuum for 2.5 h, then dissolved in 6 ml DMF, treated with 
benzyl bromide (166 µl, 1.4 mmol) and heated to 100 °C overnight.  In the morning, the reaction was 
cooled to room temperature and poured into a mixture of ethyl acetate (10 ml) and saturated NaHCO3 (5 
ml).   The layers were separated, and the organic layer was washed with brine, dried (Na2SO4), filtered 
and concentrated in vacuo.  Flash column chromatography (SiO2, 20%-30% ethyl acetate/hexanes) 
O
OMe
MeOMeO
MeOOMe
O
OMe
MeO
MeOOMe
MeO
OMeOMeO
OMe
MeO OMe
O
OMe
MeOMeO
HOOMe
O
OMe
MeOHO
MeOOMe
O
OMe
HOMeO
MeOOMe
O
OH
MeOMeO
MeOOMe
O
OMe
MeO
HOOMe
MeO
O
OMe
HO
MeOOMe
MeO
O
OMe
MeO
MeOOMe
HO
O
OH
MeO
MeOOMe
MeO
OMeOMeO
OMe
MeO OH
OMeOHO
OMe
MeO OMe
OHOMeO
OMe
MeO OMe
OMeOMeO
OMe
HO OMe
Glc Gal Man
1
1-A
1-B
1-C
1-D
2
2-A
2-B
2-C
2-D
3
3-A
3-B
3-C
3-D
O
OMe
MeOMeO
MeO
OBn
O
OMe
MeOMeO
HO
OBn
O
OMe
MeOHO
MeO
OBn
O
OMe
HOMeO
MeO
OBn
O
OH
MeOMeO
MeO
OBn
4
4-A
4-B
4-C
4-D
Glc
 11 
afforded compounds 1-F (90 mg, 35%) and 1-G (46 mg, 17%), which were taken forward without any 
further purification. 
Compound 1-F (81 mg, 0.2 mmol) was suspended in 2 ml 70% aqueous HOAc and heated to 70 °C 
overnight.  In the morning, the reaction was cooled to room temperature, concentrated and coevaporated 
with toluene (3x).  The resulting residue was dissolved in 0.77 ml DMSO and treated with 0.06 ml 50% 
aqueous NaOH and 0.09 ml MeI.  After 3 h the reaction was diluted with water and extracted with ethyl 
acetate (3X).  The pooled organics were washed with H2O and brine, dried (Na2SO4), filtered and 
concentrated in vacuo.  The resulting residue was passed through a silica gel column, eluting with 1:1 
ethylacetate:hexanes to afford, after removal of the solvent, 32 mg of an oil.  This oil was dissolved in 0.6 
ml DMF and 0.3 ml ethyl acetate, treated with 19 mg 20% Pd(OH)2/C and placed under an H2 
atmosphere.  After 14 h the reaction was treated with 0.15 mL ethyl acetate, 2 drops HOAc and 8 mg 20% 
Pd(OH)2/C.  After stirring for an additional 10 h the reaction was filtered through Celite and concentrated.  
Flash column chromatography (SiO2 7:3 ethyl acetate:hexanes) afforded compound 1-A (20 mg, 95%) 1H 
NMR (CDCl3, 500 MHz): δ = 4.75 (d, J = 3.5 Hz, 1H), 3.64 (s, 3H), 3.60-3.54 (m, 4 H), 3.51 (s, 3H), 
3.40 (s, 6H), 3.34 (t, J = 8 Hz, 1H), 3.19 (t, J = 8 Hz, 1H); 13C NMR (CDCl3, 126 MHz): δ = 99.2, 84.4, 
79.3, 72.3, 70.9, 70.2, 60.9, 60.3, 59.2, 55.3; HRMS (ESI-TOF) calcd for C10H20O6Na: 259.1152 (M+Na), 
found: 259.1158. 
α-methyl-2,4,6-triemthylglucopyranoside (1-B).  Compound 1-G (66 mg, 0.18 mmol) was 
suspended in 70% aqueous HOAc (1.5 ml) and heated to 70 °C overnight.  In the morning, the reaction 
was cooled to room temperature and concentrated.  The resulting residue was dissolved in DMSO (0.64 
ml) and treated with 50% aqueous NaOH (0.07 ml) and MeI (0.07 ml).  After 3 h the reaction was diluted 
with H2O and extracted with ethyl acetate (3X).  The pooled organic layers were washed with H2O and 
brine, dried (Na2SO4), filtered and concentrated in vacuo.  The resulting residue was passed through a 
silica gel plug eluting with ethyl acetate.  Following removal of the solvents, the residue was dissolved in 
DMF (0.5 ml) and ethyl acetate (0.25 ml), treated with 20% Pd(OH)2/C and placed under a H2 
atmosphere.  After 24 h, the reaction was filtered through Celite and concentrated in vacuo.  Flash column 
chromatography (SiO2, 7:3 ethyl acetate:hexanes) afforded 1-B (16 mg, 38%) as a colorless oil.  1H NMR 
(CDCl3, 500 MHz): δ = 4.89 (d, J = 3.5 Hz, 1H), 3.91 (t, J = 9 Hz, 1H), 3.62-3.59 (m, 3H), 3.56 (s, 3H), 
3.49 (s, 3H), 3.42 (s, 3H), 3.41 (s, 3H), 3.28-3.25 (m, 1H), 3.20 (dd, J = 10 Hz, 3.5 Hz, 1H).  13C NMR 
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(CDCl3, 126 MHz): δ = 97.1, 81.7, 79.5, 73.6, 71.5, 70.1, 60.9, 59.6, 58.8, 55.7. HRMS (ESI-TOF) calcd 
for C10H20O6Na: 259.1152 (M+Na), found: 259.1155. 
O
OMeHO
O
OPh
HO
1-E
O
OMeMeO
O
OPh
MeO
O
OMeMeO
HO
TBSO
MeO
O
OMeMeO
BnO
HO
MeO
O
OMeMeO
HO
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MeI, DMSO,
50%, NaOH
       91%
i. BH3•THF,
   Cu(OTf)2  (76%)
ii. TBSCl, imidazole
    DMF  (50%)
i. NaH, BnBr,
   TBAI, DMF  (98%)
ii. TBAF, THF  (85%)
i. MeI, 50% NaOH,
   DMSO  (71%)
ii. 20% Pd(OH)2/C,
    H2, 2:1 DMF/EtOAc
              73%
1-C
 
α-methyl-2,3,6-triemthylglucopyranoside (1-C).  Compound 1-E (100 mg, 0.33 mmol) was placed 
in a sealed tube which had been purged with argon and treated with a 1 M solution of BH3·THF in THF 
(1.65 ml).  After 10 min the reaction was treated with Cu(OTf)2 (6 mg, 16 µmol) and sonicated.  After an 
additional 10 min the reaction was treated with 6 mg Cu(OTf)2.  After an additional 30 min the reaction 
was quenched with Et3N, diluted with MeOH and concentrated.  The resulting residue was passed through  
a silica plug eluting with ethyl acetate to afford a solid (59 mg, 76%).  This solid was dissolved in DMF 
(4.6 ml) and treated with TBSCl (59 mg, 0.39 mmol) and imidazole (51 mg, 0.76 mmol).  After 3 h, the 
reaction was diluted with ethyl acetate and washed with H2O (2X).  The washes were back extracted with 
ethyl acetate (2X) and the pooled organics were dried (Na2SO4), filtered and concentrated in vacuo.  Flash 
column chromatography (SiO2, 3:7 ethyl acetate:hexanes) afforded an oil (45 mg).  This oil was dissolved 
in THF (1 ml) and treated with 60% NaH (30 mg, 0.75 mmol).  After stirring for 1 h the reaction was 
treated with benzyl bromide (70 µl, 0.59 mmol) and TBAI (7 mg, 21 µl).  The reaction was stirred for an 
additional 48 h, then cooled to 0 °C, quenched with MeOH and concentrated.  The residue was dissolved 
in ethyl acetate, washed with H2O (2X), dried (Na2SO4), filtered and concentrated in vacuo.  Flash 
column chromatography (SiO2. 1:9 ethyl acetate:hexanes) afforded an oil.  The oil was dissolved in THF 
(1.7 ml), cooled to 0 °C and treated with a 1 M solution of TBAF in THF (0.13 ml, 0.13 mmol).  After 1 h 
the reaction was warmed to room temperature, stirred for 1 h, then treated with 0.6 ml TBAF solution.  
This operation was repeated one more time, the reaction was diluted with ethyl acetate, washed with 
saturated aqueous NH4Cl and brine, dried (Na2SO4), filtered and concentrated in vacuo.  Flash column 
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chromatography (SiO2, 7:3 ethyl acetate:hexanes) afforded an oil (32 mg, 42%) which was carried 
forward without any further purification. 
The oil was dissolved in DMSO (1 ml) and treated with 50% aqueous NaOH (0.1 ml) and MeI (1.2 
ml).  After 1 h, the reaction was diluted with H2O and extracted with ethyl acetate (3X).  The pooled 
organics were dried (Na2SO4), filtered and concentrated in vacuo.  The resulting residue (19.8 mg, 0.54 
mmol) was dissolved in DMF (0.4 ml) and ethyl acetate (0.2 ml), treated with 20% Pd(OH)2/C and placed 
under a H2 atmosphere.  After 24 h, the reaction was treated with an additional 12 mg 20% Pd(OH)2/C 
and 2 drops HOAc.  After an additional 4h, the reaction was filtered through Celite and concentrated.  
Flash column chromatography (SiO2, 7:3 ethyl acetate:hexanes) afforded 1-C (9.3 mg, 73%) as a 
colorless oil.  1H NMR (CDCl3, 600 MHz):  δ = 4.86 (d, J = 3.6 Hz, 1H), 3.71-3.96 (m, 1H), 3.64-3.62 
(m, 2H), 3.63 (s, 3H), 3.55-3.50 (m, 1H), 3.51 (s, 3H), 3.49-3.45 (m, 1H), 3.46 (s, 3H), 3.43 (s, 3H), 3.26-
3.24 (m, 1H); 13C NMR (CDCl3, 600 MHz): 98.4, 83.6, 82.6, 72.8, 71.5, 70.5, 62.1, 60.4, 59.4, 56.1; 
HRMS (ESI-TOF) calcd for C10H20O6Na: 259.1152 (M+Na), found: 259.1154. 
O
OMeHO
HO
OH
HO
i. TBSCl, Et3N,
   DMAP  (41%)
ii. NaH, MeI, 
    THF  (83%)
iii. TBAF, THF
         (57%)
O
OMeMeO
MeO
OH
MeO 1-D
 
α-methyl-2,3,4-triemthylglucopyranoside (1-D).  α-methyl glucose (500 mg, 2.5 mmol) was 
suspended in CH2Cl2 (5 ml) and treated with Et3N (0.8 ml, 5.7 mmol), DMAP (31 mg, 0.25 mmol) and 
TBSCl (425 mg, 2.8 mmol).  After stirring overnight, the solution was filtered and concentrated.  The 
resulting residue was passed through a plug of silica gel eluting with 7:13 ethyl acetate:hexanes to afford 
317 mg (41%) of an oil.  This oil was dissolved in THF (14 ml), cooled to 0 °C and treated with 60% 
NaH (293 mg, 12.2 mmol).  After 10 min, MeI (2.5 ml, 41 mmol) was added and the reaction allowed to 
warm to room temperature overnight.  In the morning, the reaction was poured into ice cold saturated 
aqueous NH4Cl solution and extracted with ethyl acetate (3X).  The pooled organic layers were dried 
(Na2SO4), filtered and concentrated in vacuo.  The residue was passed through a silica gel plug eluting 
with 1:1 ethyl acetate:hexanes and concentrated.  The residue was dissolved in THF (5 ml), cooled to 0 
°C and treated with a 1 M solution of TBAF (0.54 ml).  The solution was stirred for 1.5 h, then treated 
with additional TBAF solution (0.18 ml).  After an additional 2 h, the reaction was diluted with ethyl 
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acetate, washed with saturated aqueous NH4Cl solution and brine, dried over Na2SO4 filtered and 
concentrated in vacuo.  Flash column chromatography (SiO2, ethyl acetate) afforded 1-D (39 mg, 27%) as 
a colorless oil.  1H NMR (CDCl3, 500 MHz): δ = 4.88 (d, J = 3.5 Hz, 1H), 3.92-3.88 (m, 1H), 3.84-3.78 
(m, 1H), 3.72 (s, 3H), 3.64 (s, 3H), 3.63-3.58 (m, 2H), 3.59 (s, 3H), 3.69 (s, 3H), 3.26-3.21 (m, 2H); 13C 
NMR (CDCl3. 126 MHz): δ = 97.9, 83.8, 82.3, 80.1, 70.9, 62.4, 61.3, 61.0, 59.5, 55.6; HRMS (ESI-TOF) 
calcd for C10H20O6Na: 259.1152 (M+Na), found: 259.1150. 
O
OMeHO
O
HO
2-E
2-F
2-G
i. Bu2SnO, 
   MeOH, 
   reflux
ii. BnBr, DMF,
   100 °C
+
O
OMeBnO
MeO OMe
MeO
O
OMeMeO
MeO OMe
BnO
i. 70% HOAc, 
   70 °C
ii. MeI, DMSO
    50% NaOH
O
OMeHO
MeO OMe
MeO
O
OMeMeO
MeO OMe
HO
2-A
2-B
20% Pd(OH)2,
H2, 2:1 DMF
EtOAc
i. 70% HOAc, 
   70 °C
ii. MeI, DMSO
    50% NaOH
20% Pd(OH)2,
H2, 2:1 DMF
EtOAc
OPh
O
OMeBnO
O
HO
OPh
O
OMeHO
O
BnO
OPh
 
α-methyl-3,4,6-triemthylgalactopyranoside (2-A).  Synthesized according to the general procedure 
for 1-A from 1-Methyl-4,6-O-(phenylmethylene)-α-D-galactopyranoside, 2-E.  1H NMR (CDCl3. 500 
MHz): δ = 4.83 (d, J = 5.0 Hz, 1H), 3.99 (dd, J = 12.5, 5.0 Hz, 1H), 3.79 (d, J = 2.5 Hz, 1H), 3.59-3.55 
(m, 1H), 3.57 (s, 3H), 3.54-3.51 (m, 1H), 3.52 (s, 3H), 3.44-3.41 (m, 2H) 3.43 (s, 3H), 3.41 (s, 3H); 13C 
NMR (126 MHz, CDCl3) δ = 99.91, 81.53, 75.45, 71.56, 69.65, 68.96, 61.52, 59.60, 58.02, 55.83.  
HRMS (ESI-TOF) calcd for C10H20O6Na: 259.1152 (M+Na), found: 259.1157. 
α-methyl-2,4,6-triemthylgalactopyranoside (2-B).  Prepared according to the general procedure for 
1-B from 2-E.  1H NMR (CDCl3, 500 MHz): δ = 4.92 (d, J = 3.5 Hz, 1H), 3.98-3.94 (m, 1H), 3.91 (ddd, J 
= 6.0 Hz, 6.0 Hz, 1.0 Hz, 1H), 3.61 (m, 1H), 3.59 (s, 3H), 3.56-3.54 (m, 2H), 3.51-3.49 (m, 1H), 3.50 (s, 
3H), 3.42 (s, 3H), 3.41 (s, 3H); 13C NMR (CDCl3, 126 MHz): δ = 97.6, 79.4, 79.3, 71.7, 70.5, 69.3, 62.1, 
59.6, 58.7, 55.8. HRMS (ESI-TOF) calcd for C10H20O6Na: 259.1152 (M+Na), found: 259.1151. 
2-E
MeI, DMSO,
50%, NaOH
i. BH3•THF,
   Cu(OTf)2  
ii. TBSCl, imidazole
    DMF
i. NaH, BnBr,
   TBAI, DMF 
ii. TBAF, THF
i. MeI, 50% NaOH,
   DMSO
ii. 20% Pd(OH)2/C,
    H2, 2:1 DMF/EtOAc
2-C
O
OMeHO
O
HO
OPh
O
OMeMeO
O
MeO
OPh
O
OMeMeO
HO
MeO
OTBS
O
OMeMeO
BnO
MeO
OH
O
OMeMeO
HO
MeO
OMe
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α-methyl-2,3,6-triemthylgalactopyranoside (2-C).  Prepared according to the general procedure for 
1-C from 2-E.  1H NMR (CDCl3, 500 MHz): δ = 4.91 (d, J = 3.5 Hz, 1H), 4.12 (m, 1H), 3.87 (t, J = 5.5 
Hz, 1H), 3.69-3.64 (m, 2H), 3.60 (dd, J = 10 Hz, 3.5 Hz, 1H), 3.55-3.52 (m, 1H), 3.51 (s, 3H), 3.50 (s, 
3H), 3.44 (s, 3H), 3.42 (s, 3H). 13C NMR (CDCl3, 126MHz): δ = 98.3, 79.6, 77.7, 72.8, 68.6, 67.5, 59.9, 
59.4, 58.1, 55.6; HRMS (ESI-TOF) calcd for C10H20O6Na: 259.1152 (M+Na), found: 259.1148. 
O
OMeHO
HO OH
HO
i. TBSCl, Et3N,
   DMAP  
ii. NaH, MeI, 
    THF 
iii. TBAF, THF
O
OMeMeO
MeO OH
MeO 2-D
 
α-methyl-2,3,4-triemthylgalactopyranoside (2-D).  Prepared according to the general procedure for 
1-D.  1H NMR (CDCl3, 600 MHz): δ = 4.92 (d, J = 3.6 Hz, 1H), 3.89-3.86 (m, 1H), 3.78-3.76 (m, 1H), 
3.69 (m, 1H), 3.66-3.64 (m, 1H), 3.57-3.54 (m, 2H), 3.57 (s, 3H), 3.51 (s, 6H), 3.41 (s, 3H); 13C NMR 
(CDCl3, 600 MHz): δ = 98.8, 81.3, 78.7, 78.2, 71.2, 63.5, 62.2, 59.9, 59.3, 56.3; HRMS (ESI-TOF) calcd 
for C10H20O6Na: 259.1152 (M+Na), found: 259.1157. 
O
OMe
OH
O
OPh
HO
3-E
i. Bu2SnO, 
   MeOH, 
   reflux
ii. BnBr, DMF,
   100 °C
        68%
O
OMe
OH
O
OPh
BnO
3-F
i. PTSA, MeOH (78%)
ii.  MeI, DMSO
    50% NaOH (82%)
iii. 20% Pd(OH)2, H2,
    2:1 DMF/EtOAc
            96%
O
OMe
OMe
MeO
MeO
HO 3-B
3-A
i.  TBSCl, imidazole
    DMF  (45% BORSM)
ii. 20% Pd(OH)2, H2,
    2:1 DMF/EtOAc  (96%)
ii. NaH, MeI, THF  (80%)
iii. TBAF, THF  (67%)
O
OMe
OH
MeO
MeO
MeO
 
α-methyl-3,4,6-triemthylmannopyranoside (3-A).  1-Methyl-4,6-O-[(R)-phenylmethylene]-α-D-
mannopyranoside (1.0 g, 3.0 mmol) and Bu2SnO (810 mg, 3.3 mmol) were dissolved in MeOH (25 ml) 
and heated to reflux.  After 1.5 h the reaction was cooled to room temperature, concentrated and pumped 
on under high vacuum for 2.5 h.  The residue was then dissolved in DMF (25 ml), treated with benzyl 
bromide (720 µl, 6 mmol) and heated to reflux overnight.  In the morning, the reaction was poured into 
ethyl acetate (50 ml) and saturated aqueous NaHCO3 (25 ml) and the layers separated.  The organic layer 
was washed with brine (2X), dried (Na2SO4), filtered and concentrated in vacuo.  Flash column 
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chromatography (SiO2, 15:6 ethyl acetate:hexanes) afforded a white foam (768 mg, 68%) which was 
carried on without further purification. 
The foam (384 mg, 1 mmol) was dissolved in DMF (19 ml) and treated with TBSCl (330 mg, 2 
mmol) and imidazole (277 mg, 4 mmol).  After 48 h, the reaction was diluted with ethyl acetate and 
washed with water (2X).  The washes were back extracted with ethyl acetate (3X), and the pooled organic 
layers were dried (Na2SO4), filtered and concentrated in vacuo.  Flash column chromatography (SiO2, 1:9 
ethyl acetate:hexanes) afforded an oil (79 mg, 14%) which was carried on without further purification.   
This oil (79 mg, 0.16 mmol) was dissolved in 0.81 ml DMF and 0.4 ml ethyl acetate, treated with 
20% Pd(OH)2/C and placed under a H2 atmosphere.  After 48 h the reaction was filtered through Celite 
and concentrated.  The resulting residue was passed through a plug of silica gel eluting with ethyl acetate.  
Following concentration, the residue was dissolved in THF (1.2 ml), cooled to 0 °C, treated with 60% NaH 
(62 mg, 1.5 mmol) and MeI (31 µl, 5.0 mmol) and allowed to warm to room temperature overnight.  In 
the morning, the reaction was quenched with saturated aqueous NH4Cl and extracted with ethyl acetate 
(3X).  The pooled organic layers were dried (Na2SO4), filtered, and concentrated in vacuo.  Flash column 
chromatography (SiO2, 1:1 ethyl acetate:hexanes) afforded an oil (45 mg, 80%) which was carried on 
without further purification. 
The oil (36 mg, 0.1 mmol) was dissolved in 0.7 ml THF, treated with a 1 M solution of TBAF in 
THF (112 µl, 0.1 mmol) and stirred overnight.  In the morning, the reaction was diluted with ethyl 
acetate, washed with saturated aqueous NH4Cl and brine, dried (Na2SO4), filtered and concentrated in 
vacuo.  Flash column chromatography (SiO2, ethyl acetate) afforded 3-A (16 mg, 67%) as a colorless oil.  
1H NMR (CDCl3, 500 MHz): δ = 4.83 (d, J = 2.0 Hz, 1H), 3.81 (t, J = 12.0 Hz, 1H), 3.71-3.60 (m, 4H), 
3.48 (s, 3H), 3.47 (s, 3H), 3.46-3.44 (m, 1H), 3.42 (s, 3H), 3.40 (s, 3H). HRMS (ESI-TOF) calcd for 
C10H20O6Na: 259.1152 (M+Na), found: 259.1154. 
α-methyl-2,4,6-triemthylmannopyranoside (3-B).  Prepared according to the general procedure for 
1-B.  1H NMR (CDCl3, 500 MHz): δ = 4.8 (d, J = 1.5 Hz, 1H), 3.83 (d, J = 8.0 Hz, 1H), 3.61 (d, J = 3.5 
Hz, 1H), 3.58-3.54 (m, 1H), 3.55 (s, 3 H), 3.52-3.49 (m, 1H), 3.47 (s, 3H), 3.45 (dd, J = 4.0 Hz, 1.5 Hz, 1 
H), 3.42 (s, 3H), 3.37 (s, 3H), 3.30 (t, J = 9.5 Hz, 1H); 13C NMR (CDCl3. 126 MHz): δ = 97.7, 80.7, 78.3, 
71.9, 71.9, 70.8, 61.1, 59.6, 59.2, 55.3. HRMS (ESI-TOF) calcd for C10H20O6Na: 259.1152 (M+Na), 
found: 259.1148. 
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i. BH3•THF,
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ii. TBSCl, imidazole
    DMF
i. NaH, BnBr,
   TBAI, DMF 
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α-methyl-2,3,6-triemthylmannopyranoside (3-C).  Prepared according to the general procedure for 
1-C.  1H NMR (CDCl3, 500 MHz): δ = 4.83 (d, J = 1.5 Hz, 1H), 3.81 (ddd, J = 9.5 Hz, 9.5 Hz, 1.5 Hz, 
1H), 3.73-3.60 (m, 5H), 3.48 (s, 3H), 3.47 (s, 3H), 3.41 (s, 3H), 3.40 (s, 3H); 13C NMR (CDCl3, 126 
MHz): δ = 98.8, 81.4, 76.1, 73.1, 71.3, 67.9, 59.9, 59.4, 57.5, 55.4; HRMS (ESI-TOF) calcd for 
C10H20O6Na: 259.1152 (M+Na), found: 259.1158. 
O
OMe
OH
HO
HO
HO
i. TBSCl, Et3N,
   DMAP  
ii. NaH, MeI, 
    THF  
iii. TBAF, THF
O
OMe
OMe
MeO
HO
MeO 3-D
 
α-methyl-2,3,4-triemthylmannopyranoside (3-D).  Prepared according to the general procedure for 
1-D.  1H NMR (CDCl3, 500 MHz): δ = 4.77 (d, J = 1.8 Hz, 1H), 3.84-3.82 (m, 1H), 3.79-3.75 (m, 1H), 
3.58-3.57 (m, 1H), 3.55 (s, 3H), 3.53-3.44 (m, 3H), 3.49 (s, 6H), 3.37 (s, 3H); 13C NMR (CDCl3, 600 
MHz):  δ = 98.1, 81.2, 77.0, 76.5, 71.8, 62.3, 60.7, 59.1, 57.7, 54.9 pp; HRMS (ESI-TOF) calcd for 
C10H20O6Na: 259.1152 (M+Na), found: 259.1164. 
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HO
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HO
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HO
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HO
O
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HO
HO
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ii. PMBCl
iii. PTSA, MeOH
        (81%)
+
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HO
MeO
OMe
MeO
O
OBn
MeO
MeO
OMe
HO
i. MeI, 50% NaOH 
   DMSO (72%)
ii. DDQ, 10:1 CH2Cl2
    H2O   (70%)
4-A
4-B
i. MeI, 50% NaOH 
   DMSO (72%)
ii. DDQ, 10:1 CH2Cl2
    H2O   (83%)
 
β-benzyl-3,4,6-triemthylglucopyranoside (4-A).  Compound 4-E (1.0 g, 2.6 mmol), Bu2SnO (650 
mg, 2.6 mmol) and Bu4NBr (84 mg, 2.6 mmol) were suspended in toluene (8.8 ml) and heated to reflux.  
After 3 h, the solution was treated with PMBCl (0.42 ml, 3.1 mmol).  After 48 h, the reaction was cooled 
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to room temperature, diluted with ethyl acetate, washed with H2O and brine, dried (Na2SO4), filtered and 
concentrated in vacuo.  Flash column chromatography (SiO2, 1:3 ethyl acetate:hexanes) afforded a 
mixture of 2- and 3-position isomers.  This mixture was suspended in MeOH (15 ml) and treated with p-
toluenesulfonic acid (65 mg).  After 2 h, the reaction was quenched with saturated aqueous NaHCO3 and 
concentrated in vacuo.  The residue was dissolved in ethyl acetate and washed with brine.  The aqueous 
layer was back extracted with ethyl acetate (2X), and the pooled organic layers were dried (Na2SO4), 
filtered and concentrated in vacuo.  Flash column chromatography (SiO2 8:2 ethyl acetate:hexanes then 
ethyl acetate) afforded C-2 isomer 4-F (147 mg, 26%) and C-3 isomer 4-G (309 mg, 55%). 
Compound 4-F was dissolved in DMSO (1.35 ml) and treated with 50% aqueous NaOH (0.14 ml) 
and MeI (0.15 ml) and stirred overnight.  In the morning, the reaction was diluted with H2O and extracted 
with ethyl acetate (3X).  The pooled organic layers were dried (Na2SO4), filtered and concentrated.  The 
residue was dissolved in CH2Cl2 (3 ml) and H2O (0.3 ml) and treated with DDQ (75 mg, 0.31 mmol).  
After 30 min, the reaction was diluted with CH2Cl2, washed with saturated aqueous NaHCO3 (2X) and 
brine, dried (Na2SO4), filtered and concentrated in vacuo.  Flash column chromatography (SiO2 6:4 ethyl 
acetate:hexanes) afforded 4-A (60 mg, 70%) as a colorless oil.  1H NMR (CDCl3, 500 MHz): δ = 7.37-
7.28 (m, 5H), 4.93 (d, J = 12.0 Hz 1H), 4.60 (d, J = 12.0 Hz, 1H), 4.31 (d, J = 8.0 Hz, 1H), 3.66 (dd, J = 
10.5 Hz, 2.0 Hz, 1H), 3.64 (s, 3H), 3.61-3.58 (m, 1H), 3.53 (s, 3H), 3.46 (t, J = 8.0 Hz, 1H), 3.42 (s, 3H), 
3.34-3.31 (m, 1H), 3.23 (t, J = 9.0 Hz, 1H), 3.19 (t, J = 9.0 Hz, 1H);  13C NMR (CDCl3, 126 MHz): δ = 
137.0, 128.4, 128.1,.127.9, 101.5, 85.9, 79.3, 74.9, 74.0, 71.2, 70.9, 60.6, 60.3, 59.3; HRMS (ESI-TOF) 
calcd for C16H24O6Na: 335.1465 (M+Na), found: 335.1466. 
β-benzyl-2,4,6-triemthylglucopyranoside (4-B).  Compound 4-G (309 mg, 0.79 mmol) was 
dissolved in DMSO (2.74 ml) and treated with 50% aqueous NaOH (0.28 ml) and MeI (0.29 ml) and 
stirred overnight.  In the morning, the reaction was diluted with H2O and extracted with ethyl acetate 
(3X).  The pooled organic layers were dried (Na2SO4), filtered and concentrated.  The residue was 
dissolved in CH2Cl2 (6.7 ml) and H2O (0.67 ml) and treated with DDQ (170 mg, 0.71 mmol).  After 30 
min, the reaction was diluted with CH2Cl2, washed with saturated aqueous NaHCO3 (2X) and brine, dried 
(Na2SO4), filtered and concentrated in vacuo.  Flash column chromatography (SiO2 6:4 ethyl 
acetate:hexanes) afforded 4-B (159 mg, 83%) as a colorless oil.  1H NMR (CDCl3, 500 MHz): δ = 7.37-
7.32 (m, 4H), 7.30-7.27 (m, 1H), 4.95 (d, J = 12.0 Hz, 1H), 4.62 (d, J = 12.0 Hz, 1H), 4.38 (d, J = 8.0 Hz, 
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1H), 3.67 (dd, J = 10.5 Hz, 2.0 Hz, 1H), 3.62-3.59 (m, 1H), 3.61 (s, 3H), 3.57 (s, 3H), 3.54 (dd, J = 9.0 
Hz, 1.5 Hz, 1H), 3.43 (s, 3H), 3.32 (ddd, J = 9.5 Hz, 4.5 Hz, 2.0 Hz, 1H), 3.23 (t, J = 9.0 Hz, 1H), 3.06 
(dd, J = 9.0 Hz, 7.5 Hz, 1H); 13C NMR (CDCl3, 126 MHz): δ 137.4, 128.3, 127.7, 127.6, 102.1, 83.2, 
79.0, 76.4, 74.7, 71.4, 70.9, 60.7, 60.5, 59.4; HRMS (ESI-TOF) calcd for C16H24O6Na: 335.1465 (M+Na), 
found: 335.1465. 
O
OBn
HO
O
OPMP
HO
4-E
i. MeI, 50% NaOH 
   DMSO
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    (33%, 2 steps)
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    (67% 2 steps)
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4-C  
β-benzyl-2,3,6-triemthylglucopyranoside (4-C).  Compound 4-E (500 mg, 1.3 mmol) was 
dissolved in DMSO (2.1 ml) and treated with 50% aqueous NaOH (0.21 ml) and MeI (0.24 ml).  After 
stirring overnight, the reaction was diluted with H2O and extracted with ethyl acetate (3X).  The pooled 
organic layers were washed with H2O, dried (Na2SO4), filtered and concentrated in vacuo.  The residue 
was dissolved in 70% aqueous HOAc (12 ml) and heated to 70 °C overnight.  In the morning, the reaction 
was cooled to room temperature, concentrated and coevaporated with toluene (3X).  The residue (172 mg) 
was dissolved in CH2Cl2 (1.5 ml), treated with Et3N (0.18 ml, 1.3 mmol), DMAP (0.6 mg, 5 µmol) and 
TBSCl (97 mg, 0.64 mmol) and stirred overnight.  In the morning, the reaction was filtered through Celite 
and concentrated.  Flash column chromatography (SiO2, 1:3 ethyl acetate:hexanes) afforded 190 mg of a 
foam which was used without any further purification. 
The foam was dissolved in toluene (2.6 ml) and treated with KOH (30 mg, 0.5 mmol), Bu4NBr (10 
mg, 0.03 mmol) and PMBCl (0.7 ml, 0.5 mmol).  After 48 h, the reaction was filtered through Celite and 
concentrated.  Flash column chromatography (SiO2, 1:3 ethyl acetate:hexanes) afforded 128 mg product 
which was used without any further purification.  This product was dissolved in THF (1.6 ml) and treated 
with 1 M TBAF in THF (0.26 ml).  After 12 h, the rxn was diluted with ethyl acetate, washed with 
saturated aqueous NH4Cl and brine, dried (Na2SO4), filtered and concentrated in vacuo.  The residue was 
dissolved in DMSO (0.82 ml) and treated with 50% aqueous NaOH (0.08 ml) and MeI (0.9 ml).  After 2 
h, the reaction was diluted with H2O and extracted with ethyl acetate (3X).  The pooled organics were 
dried (Na2SO4), filtered and concentrated in vacuo.  The residue was passed through a plug of silica 
eluting with 1:1 ethyl acetate: hexanes and concentrated to an oil.  The oil was dissolved in CH2Cl2 (10 
ml) and H2O (1 ml) and treated with DDQ (254 mg, 1.0 mmol).  After 1 h, the reaction was diluted with 
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CH2Cl2, washed with saturated aqueous NaHCO3 (2X) and brine, dried (Na2SO4), filtered and 
concentrated.  Flash column chromatography (SiO2, 8:2 ethyl acetate:hexanes) afforded 4-C (33 mg, 
12%) as a colorless oil.  1H NMR (CDCl3, 500 MHz): δ = 7.38-7.27 (m, 5H), 4.94 (d, J = 12.0 Hz, 1H), 
4.63 (d, J = 12.0 Hz, 1H), 4.38 (d, J = 7.8, 1H), 3.67 (dd, J = 10.7, 2.0, 1H), 3.63 (s, 3H), 3.63-3.58 (m, 
1H), 3.59 (s, 3H), 3.54 (dd, J = 9.1, 1.4, 1H), 3.42 (s, 3H), 3.41-3.38 (m, 1H), 3.15-3.09 (m, 1H), 3.06 
(dd, J = 9.2, 7.8, 1H).  13C NMR (126 MHz, CDCl3) δ = 128.76, 128.15, 128.08, 102.58, 83.57, 79.46, 
76.79, 75.11, 71.78, 71.32, 61.14, 60.87, 59.80. HRMS (ESI-TOF) calcd for C16H24O6Na: 335.1465 
(M+Na), found: 335.1461. 
O
OBn
HO
HO
OH
HO
i. TBSCl, Et3N,
   DMAP 
ii. NaH, MeI, 
    THF
iii. TBAF, THF
O
OBn
MeO
MeO
OH
MeO 1-D
 
β-benzyl-2,3,4-triemthylglucopyranoside (4-D).  Starting from benzyl-β-D-glucopyranoside, 4-E, 
prepared using the general procedure described for compound 1-D.  1H NMR (CDCl3, 500 MHz): δ = 
7.37-7.28 (m, 5H), 4.87 (d, J = 12.0 Hz, 1H), 4.67 (d, J = 12.0 Hz, 1H), 4.40 (d, J = 7.5 Hz, 1H), 3.86 (dd, 
J = 11.5 Hz, 2.5 Hz, 1H), 3.70 (dd, J =12.0 Hz, 4.5 Hz, 1H), 3.62 (s, 3H), 3.60 (s, 3H), 3.55 (s, 3H), 3.24-
3.19 (m, 1H), 3.18-3.13 (m, 2H), 3.06-3.03 (m, 1H); 13C NMR (CDCl3, 126 MHz): δ = 137.8, 128.9, 
128.3, 128.2, 103.0, 86.7, 84.3, 79.9, 75.3, 71.9, 62.5, 61.3, 61.0, 60.9; HRMS (ESI-TOF) calcd for 
C16H24O6Na: 335.1465 (M+Na), found: 335.1464. 
 
Synthesis of Monosaccharide Substrates 
See materials section for references to substrates previously reported in the literature. 
 1-benzyl-2,3,4,6-tetramethyl-β-galactopyranoside (6).  To a suspension of 0.152 g 2,3,4,6-
tetramethylgalactose (0.630 mmol, 1 equiv),  0.0641 g KOH (1.14 mmol, 1.8 equiv), and 0.0067 g 18-
crown-6 (0.025 mmol, 0.04 equiv) in THF (5 mL, ) under N2 was added 0.084 mL of benzyl bromide 
(0.70 mmol, 1.1 equiv).  The mixture was allowed to stir at room temperature for 19 h, and diluted with 
water (50 mL).  The resulting solution was extracted with 3x25 mL CH2Cl2.  The combined organic 
extracts were dried over MgSO4, filtered, and concentrated to provide a yellow oil.  The crude product 
was purified by SiO2 chromatography eluting with ethyl acetate hexanes to provide 0.148g (71%) 6 as a 
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5:1 (β/α) mixture of anomers.  1H NMR (300 MHz, CDCl3): δ 7.23-7.44 (m, 7H), 5.05 (d, J = 3.03 Hz, 
0.2H, α anomer), 4.94 (d, J = 12.1 Hz, 1H, β anomer), 4.72 (d, J = 12.2 Hz, 0.28H, α anomer), 4.53-4.67 
(m, 1.2 H, doublet for β anomer at δ 4.62 wth J = 12.1 Hz), 4.35 (d, J = 7.6 Hz, 1H, β anomer), 3.38-3.69 
(m, 24H, methyl singlets for β anomer at δ 3.42, 3.53, 3.58, and 3.61), 3.14 (dd, J1 = 9.7 Hz, J2 = 3.1 Hz, 
1H, β anomer).  13C NMR (75 MHz, CDCl3): δ 137.89, 128.49, 127.86, 127.72, 102.83, 83.98, 80.90, 
73.26, 75.04, 70.97, 70.82, 61.53, 61.15, 59.49, 58.64.  HRMS-FAB+ (m/z): [M]+ calcd for C17H25O6, 
325.1651; found, 325.1636. 
 1-benzoyl-2,3,4,6-tetramethyl-β-galactopyranoside (7).  To a solution of 0.503 g 2,3,4,6-
tetramethylgalactose (2.10 mmol, 1 equiv) and 0.90 mL triethylamine (6.3 mmol, 3 equiv) in 10 mL 
CH2Cl2 was added in a drop-wise fashion 0.30 mL benzoyl chloride (2.5 mmol, 1.2 equiv).  The solution 
was allowed to stir at room temperature for 15 h, and the reaction mixture was quenched with 50 mL 
water.  The organic layer was removed and the aqueous layer was extracted with 3x25 mL CH2Cl2.  The 
combined organic layers were dried using MgSO4, filtered, and concentrated to provide a yellow oil.  The 
crude product was purified by SiO2 chromatography eluting with 30% ethyl acetate/hexanes to provide 
0.546 g 7 (75%) as a white solid.  1H NMR (300 MHz, CDCl3) δ 8.15 – 8.05 (m, 2H), 7.63 – 7.52 (m, 
1H), 7.50 – 7.38 (m, 2H), 5.71 (d, J = 8.1, 1H), 3.78 – 3.63 (m, 4H), 3.62 (s, 3H), 3.57 (s, 6H), 3.52 (dd, J 
= 10.7, 5.2, 1H), 3.38 (s, 3H), 3.31 (dd, J = 9.7, 3.1, 1H).  13C NMR (75 MHz, CDCl3) δ 165.13, 133.73, 
130.30, 129.54, 128.63, 95.14, 84.09, 79.84, 74.73, 73.97, 70.19, 61.68, 61.29, 59.42, 58.70.  HRMS-
FAB+ (m/z): [M]+ calcd for C17H23O7, 339.1428; found, 339.1444. 
 1,2,3,4-tetramethoxymethyl-α-xylopyranoside (21).  Initial studies using a mixture of α- and β- 
tetramethoxymethylxylopyranosides suggested that only the α-anomer was consumed in the 
bioconversion.  This α/β-mixture was prepared directly from xylose and MOMCl as described below.  In 
order to unambiguously determine the substrate specificity of this reaction, the pure α-anomer was also 
prepared. 
Trimethylsilyl-2,3,4-tri-O-acetyl-α-D-xylopyranoside (21-B).  To a solution of 2,3,4-tri-O-acetyl-D-
xylopyranoside (2.0 g, 7.2 mmol) in dry DCM (20 mL) was added Et3N (1.5 mL, 10.8 mmol) and then 
TMSCl (1.1 mL, 8.6 mmol). After 1 h, 21-A (2.2 g, 88% of α-/β-mixture) was obtained by filtration in 
Al2O3 with DCM as solvent and used directly in the next step without any further purification. 
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TMSOTf (37 μL, 0.2 mmol) was added to a solution of 21-A (1.4g, 4 mmol) in dry DCM (20 mL). 
The mixture was stirred at room temperature for 8 h. After addition of Et3N (140 μL, 1.0 mmol), the 
mixture was dried in vacuo and 21-B (1.22g, 88%) was obtained as colorless oil by flash chromatography 
(SiO2 1:7 ethyl acetate:hexanes). 1H NMR (400 MHz, CDCl3) δ 5.44 (t, J = 9.7, 1H), 5.26 (d, J = 3.2, 
1H), 4.91 (dd, J = 17.4, 8.8, 1H), 4.71 (dd, J = 10.0, 3.3, 1H), 3.71 (d, J = 8.2, 2H), 2.01 (s, 3H), 1.99 (s, 
6H), 0.12 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 170.43, 170.40, 170.22, 90.58, 72.27, 69.90, 69.76, 
58.38, 21.05 (2C), 20.97, 0.00 (3C). HRMS (ESI-TOF) calcd for C14H24O8Si: 371.1133 (M+Na), found: 
371.1145. 
Methoxymethyl 2,3,4-tri-O-acetyl-α-D-xylopyranoside (21-C)  To a solution of 21-B (800 mg, 2.3 
mmol), dimethoxylmethane (1.0 mL, 11.5 mmol) and acetone (0.85 mL, 11.5 mmol) in dry DCM (10 
mL) at 0 °C was added TMSOTf (40 μL, 0.23 mmol). The mixture was finished in few minute and 
quenched by addition of Et3N (160 μL, 1.15 mmol). The solution was diluted with DCM (50 mL), washed 
with saturated NaHCO3 and brine, and dried with MgSO4. Concentration in vacuo and flash 
chromatography (SiO2 2:3 ethyl acetate:hexanes) afforded 21-C (660 mg, 90%) as colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 5.51 (t, J = 9.8, 1H), 5.24 (d, J = 3.7, 1H), 4.99 (ddd, J = 10.6, 9.5, 6.0, 1H), 4.89 
(dd, J = 10.3, 3.8, 1H), 4.87 (d, J = 6.7, 1H), 4.59 (d, J = 6.6, 1H), 3.82 (dd, J = 10.9, 6.0, 1H), 3.68 (t, J = 
10.8, 1H), 3.40 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.27, 
170.13, 170.10, 93.43, 92.73, 70.79, 69.72, 69.44, 59.07, 56.12, 20.95, 20.89, 20.80. HRMS (ESI-TOF) 
calcd for C13H20O9: 343.0999 (M+Na), found: 343.1016. 
Methoxymethyl α-D-xylopyranoside (21-D)  21-C (200 mg, 0.625 mmol) was dissolved in 10 mM 
NaOMe/MeOH (3 mL). After 1h, 21-D (120 mg, 99%) was obtained as colorless oil by chromatography 
(iatro beads, MeOH). 1H NMR (400 MHz, CDCl3) δ 5.29 (d, J = 2.4, 1H), 5.06 (d, J = 3.7, 1H), 4.88 (d, J 
= 6.4, 1H), 4.74 (d, J = 2.6, 1H), 4.64 (d, J = 6.4, 1H), 4.32 (d, J = 7.9, 1H), 3.77 – 3.48 (m, 2H), 3.43 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 95.71, 93.66, 74.58, 71.90, 70.12, 62.33, 56.42. HRMS (ESI-TOF) 
calcd for C7H14O6: 217.0683 (M+Na), found: 217.0683. 
1,2,3,4-tetra-O-methoxymethyl-α-D-xylopyranoside (21)  DIEA (1.0 mL, 6 mmol) and MOMCl (340 
μL, 4.5 mmol) were added to a solution of 21-D (100 mg, 0.5 mmol) in DCM (5 mL) at 0 °C.  The 
reaction was kept at room temperature overnight untill disappearance of starting material as judged by 
TLC.  The residue was dried in vacuo and submit to flash chromatography (SiO2 2:3 ethyl 
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acetate:hexanes) to give 21 (140 mg, 86%) as a light yellow oil. 1H NMR (500 MHz, CDCl3) δ 5.11 (d, J 
= 3.6, 1H), 4.91 (d, J = 6.5, 1H), 4.83 (dd, J = 25.0, 6.3, 2H), 4.78 (t, J = 6.8, 2H), 4.71 (d, J = 6.6, 1H), 
4.67 (d, J = 6.8, 1H), 4.63 (d, J = 6.5, 1H), 3.94 – 3.86 (m, 1H), 3.83 – 3.74 (m, 1H), 3.64 – 3.52 (m, 3H), 
3.46 (s, 3H), 3.42 (s, 3H), 3.41 (s, 3H), 3.36 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 98.32, 97.78, 97.55, 
95.10, 93.82, 77.64, 77.50, 77.36, 61.50, 56.62, 56.28, 56.00, 55.93. HRMS (ESI-TOF) calcd for 
C13H26O9: 349.1469 (M+Na), found: 349.1453. 
 
 Preparative Scale Bioconversions 
 
 1,3,4,6-tetramethyl-α-galactopyranoside (9).  Prepared using 162.2 mg 2 (0.6479 mmol, 1 equiv), 
8.0 mL 5E5 (81 μM, 0.001 equiv), 49.59 mg NADP+ (0.06479 mmol, 0.1 equiv), 1.9927 g glucose-6-
phosphate (6.479 mmol, 10 equiv), 150 μL glucose-6-phosphate dehydrogenase (2 u/mL total volume) 
and 57 mL KPi.  The product was purified by SiO2 chromatography eluting with ethyl acetate to provide 
0.0741 g 11 (48%) as a colorless oil.  1H NMR (600 MHz, CDCl3) δ 4.81 (d, J = 3.9, 1H), 4.00 – 3.94 (m, 
1H), 3.84 (t, J = 6.5, 1H), 3.72 (d, J = 2.1, 1H), 3.58 – 3.55 (m, 1H), 3.55 (s, 3H), 3.51 (s, 3H), 3.52 – 3.48 
(m, 1H), 3.41 (s, 3H), 3.43 – 3.37 (m, J = 11.8, 1H), 3.39 (s, 3H).  13C NMR (151 MHz, CDCl3) δ 99.47, 
81.12, 74.99, 71.13, 69.24, 68.57, 61.11, 59.19, 57.61, 55.43.  HRMS-FAB+ (m/z): [M]+ calcd for 
C10H21O6, 237.1338; found, 237.1332. 
 1,2,4,6-tetramethyl-β-galactopyranoside (11).  Prepared using 56.70 mg 5 (0.225 mmol, 1 equiv), 
4.0 mL E12r12 (56 μM, 0.001 equiv), 16.73 mg NADP+ (0.0225 mmol, 0.1 equiv), 0.6842 g glucose-6-
phosphate (2.25 mmol, 10 equiv), 44 μL glucose-6-phosphate dehydrogenase (2 u/mL total volume) and 
45 mL KPi.  The product was purified by SiO2 chromatography eluting with ethyl acetate to provide 
0.0347 g 11 (65%) as a colorless oil.  1H NMR (600 MHz, CDCl3) δ 4.13 (d, J = 7.6, 1H), 3.62 – 3.59 (m, 
1H), 3.59 (s, 3H), 3.56 (s, 3H), 3.56 - 3.53 (m, 4H), 3.50 (s, 3H), 3.39 (s, 3H), 3.17 (dd, J = 9.2, 7.6, 1H).  
13C NMR (75 MHz, CDCl3) δ 104.65, 81.82, 78.12, 74.08, 73.54, 70.99, 61.88, 61.09, 59.44, 56.91.  
HRMS-FAB+ (m/z): [M]+ calcd for C10H21O6, 237.1338; found, 237.1340. 
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 1-benzoyl-2,4,6-trimethyl-β-galactopyranoside (12).  Prepared using 0.1020 g 7 (0.294 mmol, 1 
equiv) dissolved in 3.6 mL DMSO, 3.68 mL B1SYN (40 μM, 0.0005 equiv), 54.64 mg NADP+ (0.0735 
mmol, 0.25 equiv), 0.8940 g glucose-6-phosphate (2.940 mmol, 10 equiv), 143 μL glucose-6-phosphate 
dehydrogenase (2 u/mL total volume), 2.92 mg superoxide dismutase (100 units/mL total volume), and 
145 mL KPi.  The product was purified by SiO2 chromatography eluting with 50% ethyl acetate/hexanes 
to provide 0.0988 g 12 (99%) as a white solid.  1H NMR (300 MHz, CDCl3) δ 8.15 – 8.04 (m, 2H), 7.58 
(dd, J = 10.4, 4.4, 1H), 7.45 (t, J = 7.6, 2H), 5.71 (d, J = 8.0, 1H), 3.85 – 3.78 (m, 1H), 3.77 – 3.66 (m, 
2H), 3.63 (s, 3H), 3.59 (s, 3H), 3.58 – 3.51 (m, J = 9.4, 5.8, 2H), 3.38 (s, 3H), 2.50 (d, J = 6.0, 1H).  13C 
NMR (75 MHz, CDCl3) δ 164.98, 133.83, 130.27, 129.45, 128.70, 95.06, 80.91, 77.85, 74.25, 74.10, 
70.19, 62.08, 61.30, 59.37.  HRMS-FAB+ (m/z): [M]+ calcd for C16H23O7, 327.1444; found, 327.1441. 
 1,2,3,4-tetramethyl-α-mannopyranoside (13).  Prepared using 0.1020 g 3 (0.4 mmol, 1 equiv), 3.25 
mL 9-10A F87Idr (118 μM, 0.001 equiv), 29.81 mg NADP+ (0.04 mmol, 0.1 equiv), 1.253 g glucose-6-
phosphate (4.01 mmol, 10 equiv), 78 μL glucose-6-phosphate dehydrogenase (2 u/mL total volume), 1.90 
mg superoxide dismutase (100 units/mL total volume), and 80 mL KPi.  The product was purified by SiO2 
chromatography eluting with ethyl acetate to provide 0.0687 g 13 (71%) as a white solid.  1H NMR (600 
MHz, CDCl3) δ 4.76 (d, J = 1.6, 1H), 3.82 (d, J = 9.6, 1H), 3.74 (d, J = 8.2, 1H), 3.56 (dd, J = 3.1, 1.8, 
1H), 3.53 (s, 3H), 3.51 – 3.49 (m, 1H), 3.48 (s, 3H), 3.48 (s, 3H), 3.47 – 3.38 (m, 2H), 3.35 (s, 3H).  13C 
NMR (75 MHz, CDCl3) δ 98.38, 81.41, 77.46, 76.75, 72.00, 62.57, 61.01, 59.37, 57.94, 55.14.  HRMS-
FAB+ (m/z): [M]+ calcd for C10H19O6, 235.1182; found, 235.1188. 
 1-benzyl-2,3,6-trimethyl-β-glucopyranoside (14).  Prepared using 0.1041 g 4 (0.3192 mmol, 1 
equiv) dissolved in 1.5 mL DMSO, 0.5 mL 9-10A F87Idr (118 μM, 0.001 equiv), 22.50 mg NADP+ 
(0.0303 mmol, 0.1 equiv), 0.8754 g glucose-6-phosphate (2.879 mmol, 10 equiv), 60 μL glucose-6-
phosphate dehydrogenase (2 u/mL total volume) and 60 mL KPi.  The reaction was stopped after only 4 
hours in order to avoid subsequent demethylation of the desired product.  The product was purified by 
SiO2 chromatography eluting with 60% ethyl acetate/hexanes to provide 0.0441 g 14 (44%) as a white 
solid.  1H NMR (600 MHz, CDCl3) δ 7.39 – 7.30 (m, 4H), 7.30 – 7.26 (m, 1H), 4.92 (d, J = 12.0, 1H), 
4.63 (d, J = 12.0, 1H), 4.42 – 4.38 (m, 1H), 3.71 – 3.63 (m, 2H), 3.62 (s, 3H), 3.58 (s, 3H), 3.57 – 3.48 
(m, 1H), 3.42 (s, 3H), 3.41 – 3.37 (m, 1H), 3.12 – 3.09 (m, 2H).  13C NMR (75 MHz, CDCl3) δ 137.41, 
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128.34, 127.71, 127.67, 104.98, 85.66, 83.47, 73.77, 72.63, 71.11, 71.01, 60.82, 60.34, 59.59.  HRMS-
FAB+ (m/z): [M]+ calcd for C16H25O6, 313.1655; found, 313.1651. 
 1-benzyl-2,3,6-trimethyl-β-galactopyranoside (15).  Prepared using 0.1022 g 6 (0.3066 mmol, 1 
equiv) dissolved in 1.5 mL DMSO, 2.75 mL 9-10A F87Idr (118 μM, 0.001 equiv), 24.50 mg NADP+ 
(0.0330 mmol, 0.1 equiv), 0.9368 g glucose-6-phosphate (2.879 mmol, 10 equiv), 60 μL glucose-6-
phosphate dehydrogenase (2 u/mL total volume) and 60 mL KPi.  The product was purified by SiO2 
chromatography eluting with 75% ethyl acetate/hexanes to provide 0.0609 g 15 (64%) as a colorless oil.  
1H NMR (600 MHz, CDCl3) δ 7.37 – 7.22 (m, 5H), 4.92 (d, J = 12.0, 1H), 4.63 (d, J = 12.0, 1H), 4.35 (d, 
J = 7.7, 1H), 4.03 (d, J = 2.6, 1H), 3.74 – 3.67 (m, 1H), 3.67 – 3.61 (m, 1H), 3.57 (s, 3H), 3.51-3.48 (m, 
1H), 3.47 (s, 3H), 3.40 (s, 3H), 3.32 (dd, J = 9.3, 7.8, 1H), 3.13 (dd, J = 9.4, 3.4, 1H).  13C NMR (75 MHz, 
CDCl3) δ 137.73, 128.54, 127.92, 127.84, 102.76, 82.84, 80.43, 73.15, 71.95, 70.99, 66.17, 61.14, 59.70, 
57.96.  HRMS-FAB+ (m/z): [M]+ calcd for C16H25O6, 313.1655; found, 313.1651. 
 1,2,4-trimethoxymethyl-α-xylopyranoside (22).  Prepared using 0.1139 g 21 (0.349 mmol, 1 equiv) 
dissolved in 1.4 mL DMSO, 4.9 mL 9-10A F87Vdr (107 μM, 0.0015 equiv), 51.40 mg NADP+ (0.0698 
mmol, 0.2 equiv), 2.1196 g glucose-6-phosphate (6.98 mmol, 20 equiv), 140 μL glucose-6-phosphate 
dehydrogenase (2 u/mL total volume) and 70 mL KPi.  The product was purified by SiO2 chromatography 
eluting with 60% ethyl acetate/hexanes to provide 0.0380 g 22 (40%) as a colorless oil.  1H NMR (600 
MHz, CDCl3) δ 5.06 (d, J = 3.7, 1H), 4.85 (d, J = 6.5, 1H), 4.78 (d, J = 6.8, 1H), 4.72 (d, J = 6.9, 1H), 
4.68 (dd, J = 14.7, 6.8, 1H), 4.57 (d, J = 6.5, 1H), 3.84 (t, J = 9.1, 1H), 3.74 – 3.66 (m, 2H), 3.55 (t, J = 
10.9, 1H), 3.51 – 3.44 (m, 2H), 3.40 (s, 3H), 3.39 (s, 3H), 3.36 (s, 3H).  13C NMR (75 MHz, CDCl3) δ 
97.28, 97.25, 94.17, 93.26, 78.49, 78.22, 71.60, 60.32, 56.01, 55.66, 55.58.  HRMS-FAB+ (m/z): [M]+ 
calcd for C13H25O9, 325.1498; found, 325.1485. 
 
 Functionalization of Mono-demethylated Monosaccharide Derivatives 
 6-fluoro-1,2,3,4-tetramethyl-α-mannopyranoside (16).  To a solution of 0.0605 g 13 (0.26 mmol, 1 
equiv) in 5 mL CH2Cl2 at 0 °C under N2 was added drop-wise 0.08 mL (diethylamino)sulfur trifluoride 
(DAST, 0.61 mmol, 2.3 equiv).  The reaction was allowed to warm to room temperature over four hours 
and quenched with 5 mL methanol and 25 mL water.  The mixture was extracted with 3x25 mL CH2Cl2, 
and the combined organic extracts were dried over MgSO4, filtered, and concentrated to give a yellow oil.  
 26 
The crude product was purified by SiO2 chromatography eluting with 40% ethyl acetate/hexanes to 
provide 0.0348 g 16 (56%) as a colorless oil.  1H NMR (300 MHz, CDCl3) δ 4.79 (d, J = 1.6, 1H), 4.74 – 
4.61 (m, 1H), 4.57 – 4.46 (m, 1H), 3.58 – 3.54 (m, 1H), 3.53 (s, 3H), 3.52 – 3.49 (m, J = 2.9, 2H), 3.48 (s, 
3H), 3.48 (s, 3H), 3.47 – 3.41 (m, J = 9.3, 1H), 3.36 (s, 3H).  13C NMR (75 MHz, CDCl3) δ 98.27 (s), 
83.61 (s), 81.40 (d, J = 1.3), 81.32 (s), 75.46 (d, J = 6.7), 71.12 (d, J = 18.2), 61.01 (s), 59.25 (s), 57.93 
(s), 55.24 (s).  19F NMR (282 MHz, CDCl3) δ -32.66 (td, J = 47.7, 26.4, 1H).  HRMS-FAB+ (m/z): [M]+ 
calcd for C10H19O5F, 238.1216; found, 238.1217. 
 6-fluoro-1,2,3,4-tetraacetyl-α-mannopyranoside (17).  To a solution of 0.0281 g 16 (0.118 mmol, 
1 equiv) in 1 mL CH2Cl2 at 0 °C under N2 was added drop-wise 0.18 mL BBr3 (1.77 mmol, 15 equiv).  
The reaction was allowed to warm to room temperature over six hours and quenched with 5 mL water.  
The CH2Cl2 was removed by rotary evaporation and the aqueous mixture was purified by anion exchange 
chromatography (Dowex).  Product-containing fractions were combined and concentrated by rotary 
evaporation to give crude 6-fluoromannopyranoside as a mixture of anomers.  To this material was added 
0.0010 g dimethylaminopyridine (0.0060 mmol, 0.05 equiv) and a stir bar.  The flask was evacuated and 
purged with N2 three times, and charged with 2 mL CH2Cl2 and 0.15 mL pyridine (1.42 mmol, 12 equiv).  
Finally, 0.1 mL acetyl chloride (1.18 mmol, 10 equiv) was added to the flask, and the mixture was stirred 
at room temperature for 12 h.  10 mL 1 M HCl was added, and the resulting mixture was extracted with 3 
x 20 mL CH2Cl2.  The combined organic extracts were dried over MgSO4, filtered, and concentrated to 
give a yellow oil.  The crude product was purified by SiO2 chromatography eluting with 40% ethyl 
acetate/hexanes to provide 0.0227 g 17 (55%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ 6.10 (d, J 
= 2.0, 0.4 H), 5.88 (s, 0.4 H), 5.49 (d, J = 3.1, 0.4 H), 5.38 (m, 1 H), 5.34 - 5.28 (d, J = 9.28, 0.6 H), 5.27 
(m, 0.6 H), 5.15 (dd, J = 10.0, 3.2, 0.6 H), 4.64 – 4.50 (m, 1H), 4.47 – 4.35 (m, 1H), 4.17 – 3.89 (m, 0.6 
H), 3.89 – 3.66 (m, 0.4 H), 2.21 (s, 1H), 2.17 (m, 3H), 2.11 (m, 2H), 2.08 (m, J = 2.3, 3H), 2.01 (d, J = 
0.7, 3H).   13C NMR (151 MHz, CDCl3) δ 170.18, 169.99, 169.79, 169.74, 169.46, 169.44, 168.34, 
168.00, 90.50, 90.24 (2C), 81.75, 80.59, 73.80, 73.67, 71.36, 71.22, 70.61, 68.64, 68.22, 68.08, 20.83, 
20.72, 20.66, 20.64, 20.62 (2C), 20.51.  19F NMR (282 MHz, CDCl3) δ -31.45 (td, J = 46.7, 21.3, 0.4 F), -
32.58 (td, J = 47.3, 23.1, 0.6 F).  HRMS-FAB+ (m/z): [M]+ calcd for C14H19O9F, 350.1013; found, 
350.0984. 
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 1-benzoyl-3-deoxy-2,4,6-trimethyl-β-galactoopyranoside (18).  To a solution of 0.106 g 12 (0.322 
mmol, 1 equiv) and 0.0022 g dimethylaminopyridine (0.016 mmol, 0.05 equiv) in 8 mL CH2Cl2 under N2 
was added 0.08 mL pyridine (1.0 mmol, 3 equiv) and 0.08 mL O-phenyl chlorothionoformate (0.55 
mmol, 1.7 equiv).  The solution was allowed to stir at room temperature over 12 hours and quenched with 
25 mL water.  The mixture was extracted with 3 x 25 mL CH2Cl2, and the combined organic extracts were 
dried over MgSO4, filtered, and concentrated to give a yellow oil.  The crude product was purified by 
SiO2 chromatography eluting with 10% ethyl acetate/hexanes to provide 0.135 g of the intermediate 
thionoester 19 (90%) as a colorless oil. 
 To a solution of 0.205 g 19 (0.430 mmol, 1 equiv) and 0.0259 g 2,2’-azobis(2-methylpropionitrile)  
(0.160 mmol, 0.36 equiv) in 20 mL toluene under N2 was added 0.35 mL tributyltin hydride (1.30 mmol, 
3 equiv).  The resulting solution was stirred at reflux for four hours.  The volatiles were removed by 
rotary evaporation, and the mixture was purified by SiO2 chromatography eluting with 10% ethyl 
acetate/hexanes to provide 0.117 g of 20 (85%) as a colorless oil.  1H NMR (300 MHz, CDCl3) δ 8.16 – 
8.04 (m, 2H), 7.62 – 7.51 (m, 1H), 7.50 – 7.38 (m, 2H), 5.81 (d, J = 7.8, 1H), 3.88 (ddd, J = 6.7, 6.1, 1.6, 
1H), 3.70 – 3.49 (m, 5H), 3.46 (s, 3H), 3.44 (s, 3H), 3.34 (s, 3H), 2.57 (ddd, J = 13.9, 4.9, 3.6, 1H).   13C 
NMR (75 MHz, CDCl3) δ 137.55, 128.67, 128.60, 127.99, 127.96, 102.55, 83.04, 76.35, 74.20, 72.80, 
71.52, 71.25, 60.99, 59.86.  HRMS-FAB+ (m/z): [M]+ calcd for C16H21O6, 309.1338; found, 309.1350. 
 3-deoxy-1,2,4,6-tetraacetylgalactoopyranoside (19).  To a solution of 0.0487 g 12 (0.157 mmol, 1 
equiv) in 1 mL CH2Cl2 at 0 °C under N2 was added drop-wise 0.23 mL BBr3 (2.36 mmol, 15 equiv).  The 
reaction was allowed to warm to room temperature over four hours and quenched with 5 mL water.  The 
CH2Cl2 was removed by rotary evaporation and the aqueous mixture was purified by anion exchange 
chromatography (Dowex).  Product-containing fractions were combined and concentrated by rotary 
evaporation to give crude 3-deoxygalactopyranoside (19) as a mixture of anomers.   
 To 0.0233 g of 19 (0.142 mmol, 1 equiv) was added 0.0010 g dimethylaminopyridine (0.0071 mmol, 
0.05 equiv) and a stir bar.  The flask was evacuated and purged with N2 three times, and charged with 2 
mL CH2Cl2 and 0.14 mL pyridine (1.70 mmol, 12 equiv).  Finally, 0.101 mL acetyl chloride (1.42 mmol, 
10 equiv) was added to the flask, and the mixture was stirred at room temperature for 6 h.  10 mL 1 M 
HCl was added, and the resulting mixture was extracted with 3 x 20 mL CH2Cl2.  The combined organic 
extracts were dried over MgSO4, filtered, and concentrated to give a yellow oil.  The crude product was 
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purified by SiO2 chromatography eluting with 40% ethyl acetate/hexanes to provide 0.0400 g 20 (85%) as 
a colorless oil.  1H NMR (300 MHz, CDCl3) δ 5.41 (d, J = 3.5, 1H), 5.18 (m, 1H), 5.08 (m, 1H), 4.57 (dd, 
J = 12.3, 2.4, 1H), 4.23 (m, 2H), 4.12 (dd, J = 12.3, 5.2, 1H), 3.81 (dd, J = 10.7, 1.8, 1H), 2.10 (s, 3H), 
2.07 (s, 3H), 2.06 (s, 3H), 2.00 (s, 3H).  13C NMR (75 MHz, CDCl3) δ 170.88, 169.97, 169.88, 169.57, 
77.73, 77.42, 74.80, 72.70, 68.07, 63.53, 21.07, 21.03 (2C), 20.93.  HRMS-FAB+ (m/z): [M]+ calcd for 
C14H21O9, 333.1185; found, 333.1196. 
 
Disaccharide Formation. 
3-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-1,2,4-tri-O-methoxymethyl-α-D-xylopyranoside (24)  A 
mixture of 22 (78 mg, 0.27 mmol), 2,3,4-tetra-O-acetyl-α-D-xylopyranosyl trichloroacetimidate12 (175 
mg, 0.42 mmol) and molecular sieves (250 mg) in dry DCM (5 mL) was stirred at room temperature for 
30 min. TMSOTF (5 μL, 27 μmol) was added at -50 °C. After 2 h at this temperature, reaction was 
quenched by Et3N (18 μL, 0.13 mmol), then allowed to reach room temperature and filtered through 
Celite. Flash column chromatography (SiO2 1:1 ethyl acetate:hexanes) afforded 24 (132 mg, 88%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.13 (ddd, J = 8.6, 6.2, 2.7, 1H), 5.09 (d, J = 3.6, 1H), 4.95 
(td, J = 8.8, 5.2, 1H), 4.92 – 4.86 (m, 3H), 4.78 (d, J = 6.8, 1H), 4.70 (q, J = 6.8, 2H), 4.63 (d, J = 6.6, 
2H), 4.15 (dd, J = 11.8, 5.2, 1H), 4.08 – 4.02 (m, 1H), 3.80 – 3.70 (m, 1H), 3.61 – 3.57 (m, 2H), 3.53 (dd, 
J = 9.8, 3.6, 1H), 3.45 (s, 3H), 3.40 (s, 3H), 3.36 (s, 3H), 3.35 – 3.30 (m, 1H), 2.05 (s, 3H), 2.04 (s, 3H), 
2.03 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.28, 170.06, 169.49, 100.63, 98.17, 97.59, 95.28, 93.75, 
78.78, 77.68, 75.42, 72.08, 71.69, 69.12, 62.20, 61.12, 56.56, 55.90, 55.69, 20.96, 20.93, 20.90. HRMS 
(ESI-TOF) calcd for C22H36O15: 563.1946 (M+Na), found: 563.1946. 
3-O-β-D-xylopyranosyl-D-xylopyranoside (25)  24 (11 mg, 20μmol) was dissolved in 10 mM 
NaOMe/MeOH solution (1 mL). After 1 h, reaction mixture was passed through iatro beads and dried. 
Then the mixture was dissolved in 2 M HCl in MeOH/H2O (1:1, 1 mL) and stirred at room temperature 
overnight. Flash chromatography (RP-C18, H2O) gives 25 (3.2 mg, 55%) as a colorless oil. 1H NMR (500 
MHz, D2O) δ 5.18 (d, J = 3.7, 1H), 4.56 (d, J = 7.9, 1H), 3.91 (dd, J = 11.5, 5.5, 1H), 3.70 – 3.64 (m, 
2H), 3.64-3.57 (m, 2H), 3.50 (dd, J = 9.4, 3.7, 1H), 3.42 (dd, J = 16.9, 7.6, 2H), 3.34 – 3.28 (m, 1H), 3.21 
(dd, J = 9.4, 7.9, 1H). 13C NMR (126 MHz, D2O) δ 97.01, 92.62, 76.21, 74.42, 73.21, 71.85, 69.79, 69.61, 
65.57, 61.32. HRMS (ESI-TOF) calcd for C10H18O9: 305.0843 (M+Na), found: 305.0845. 
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Assignment of Sugar Structures: 
 1,3,4,6-tetramethyl-α-galactopyranoside (9).  The structure of 9 was assigned by comparing its GC 
chromatogram with those of authentic standards.  Chromatograms for the 2, 3, 4, and 6-OH tetramethyl-
α-galactopyranosides (2A-D) are shown, and a mixture of these compounds was spiked with 9.  The 1-
OH tetramethylgalactopyranoside elutes significantly later than the four isomers shown.  This assignment 
was verified by COSY, HSQC, and HMBC NMR spectroscopy as described for 11, 14, and 22.  NMR 
spectra are available upon request. 
 
 
1,2,4,6-tetramethyl-β-galactopyranoside (11).  The structure of 11 was assigned by 1H, 13C, COSY, 
HSQC, and HMBC NMR spectroscopy.  Single perspectives of these spectra are shown, and the data files 
are available upon request. 
 
 
 
 
 
 
2-A (2OH) 
2-A, B, C, D mix 
2-A, B, C, D mix + 9 
2-A 2-B 
2-C 
2-D 
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11-1H: 
 
11-13C: 
11- 
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COSY: 
 
11-HSQC: 
 
 32 
11-HMBC: 
 
 1-benzoyl-2,4,6-trimethyl-β-galactopyranoside (12).  Single crystals of 12 suitable for X-ray 
analysis were obtained by slow evaporation of CH2Cl2 from a solution of the compound. Crystallographic 
data have been deposited at the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK and copies can be 
obtained on request, free of charge, by quoting the publication citation and the deposition number 
673244.   
Crystals were mounted on a glass fiber using Paratone oil then placed on the diffractometer under a  
nitrogen stream at 100K.  Refinement of F2 against ALL reflections.  The weighted R-factor (wR) and 
goodness of fit (S) are based on F2, conventional R-factors (R) are based on F, with F set to zero for 
negative F2. The threshold expression of F2 > 2σ( F2) is used only for calculating R-factors(gt) etc. and is 
not relevant to the choice of reflections for refinement.  R-factors based on F2 are statistically about twice 
as large as those based on F, and R-factors based on ALL data will be even larger.  All esds (except the 
esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix.  The cell 
esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; 
correlations between esds in cell parameters are only used when they are defined by crystal symmetry.  
An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.  
 
Crystal data and structure refinement 
Empirical formula      C16H22O7  
Formula weight      326.34  
Crystallization Solvent     Cyclohexane/dichloromethane  
Crystal Habit      Needle  
Crystal size      0.41 x 0.12 x 0.11 mm3  
Crystal color  Colorless   
Data Collection   
Type of diffractometer     Bruker KAPPA APEX II  
Wavelength       0.71073 Å MoKα   
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Data Collection Temperature    100(2) K  
θ range for 9998 reflections used  
in lattice determination     2.76 to 36.01°  
Unit cell dimensions    a = 12.5013(6) Å  
       b = 4.6992(2) Å  β= 93.488(3)°  
       c = 13.5074(6) Å  
      Volume 792.04(6) Å3  
Z       2  
Crystal system     Monoclinic  
Space group       P21  
Density (calculated)    1.368 Mg/m3  
F(000)      348  
Data collection program    Bruker APEX2 v2.1-0  
θ range for data collection    1.63 to 36.47°  
Completeness to θ = 36.47°   99.6 %   
Index ranges      -20 ≤ h ≤ 20, -7 ≤ k ≤ 7, -22 ≤ l ≤ 22  
Data collection scan type     ω scans; 40 settings  
Data reduction program     Bruker SAINT-Plus v7.34A  
Reflections collected    68204  
Independent reflections    7680 [Rint= 0.0635]  
Absorption coefficient    0.107 mm-1  
Absorption correction    None  
Max. and min. transmission (calc)   0.9883 and 0.9573 
Structure solution and Refinement   
Structure solution program    SHELXS-97 (Sheldrick, 1990)  
Primary solution method     Direct methods  
Secondary solution method    Difference Fourier map  
Hydrogen placement     Difference Fourier map  
Structure refinement program    SHELXL-97 (Sheldrick, 1997)  
Refinement method     Full matrix least-squares on F2  
Data / restraints / parameters   7680 / 1 / 296  
Treatment of hydrogen atoms    Unrestrained  
Goodness-of-fit on F2    1.647  
Final R indices  
[I>2σ(I),  6003 reflections]   R1 = 0.0413, wR2 = 0.0512  
R indices (all data)     R1 = 0.0599, wR2 = 0.0523  
Type of weighting scheme used   Sigma  
Weighting scheme used    w=1/σ2(Fo2)  
Max shift/error      0.001  
Average shift/error      0.000  
Absolute structure determination   Not able to determine reliably  
Absolute structure parameter   -0.5(4)  
Largest diff. peak and hole    0.340 and -0.397 e.Å-3  
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 1,2,3,4-tetramethyl-α-mannopyranoside (13).  The structure of 13 was assigned by comparing its 
GC chromatogram with those of authentic standards.  Chromatograms for the 2, 3, 4, and 6-OH 
tetramethyl-α-mannopyranosides (3-A-D) are shown (the 2-OH and 4-OH isomer co-elute), and a mixture 
of these compounds was spiked with 13.  The 1-OH tetramethylmannopyranoside elutes significantly 
later than the four isomers shown.  This assignment was verified by COSY, HSQC, and HMBC NMR 
spectroscopy as described for 11, 14, and 22.  NMR spectra are available upon request. 
 
 
 1-benzyl-2,3,6-trimethyl-β-glucopyranoside (14).  The structure of 14 was assigned by comparing 
its GC chromatogram with those of authentic standards.  Chromatograms for the 2, 3, 4, and 6-OH 1-
benzyltrimethyl-β-glucopyranosides are shown.  This assignment was verified by COSY, HSQC, and 
HMBC NMR spectroscopy as described for 11, 15, and 22.  NMR spectra are available upon request. 
 
 
 
3-D (6OH) 
3-A, B, C, D mix 
3-A, B, C, D mix + 13 
3-A/C, 2/4OH 
3-D, 6OH 
3-B, 3OH 
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 1-benzyl-2,3,6-trimethyl-β-galactopyranoside (15).  The structure of 15 was assigned by 1H, 13C, 
COSY, HSQC, and HMBC NMR spectroscopy.  Single perspectives of these spectra are shown, and the 
data files are available upon request. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4-C, 4OH 
4-A, B, C, D mix 
4-A, B, C, D mix + 14 
4-D, 6OH 
4-B, 3OH 4-C, 4OH 
4-A, 2OH 
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15-1H: 
 
15-13C: 
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15-COSY: 
 
15-HSQC: 
 
 39 
15-HMBC: 
 
 1,2,4-trimethoxymethyl-α-xylopyranoside (22).  The structure of 22 was assigned by 1H, 13C, 
COSY, HSQC, and HMBC NMR spectroscopy.  Single perspectives of these spectra are shown, and the 
data files are available upon request. 
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22-1H: 
 
22-13C: 
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22-COSY: 
 
22-HSQC: 
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22-HMBC: 
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